Following NICE’s rejection last week for Tagrisso, AstraZeneca argues that the health technology appraisal body was wrong not to take the company’s real-world data into account when considering whether the lung cancer drug should be granted “end of life” status.
AstraZeneca has said it will appeal against last week’s decision by the National Institute for Health and Care Excellence (NICE) to recommend that its drug, Tagrisso, should not be used on England’s National Health Service as a first line treatment for a certain type of lung cancer.
NICE issued final guidance on 5 July saying that Tagrisso (osimertinib) was not an acceptable use of NHS resources for...
Blenrep, GSK’s multiple myeloma therapy, faced a major setback when it was withdrawn from the market in 2022. The drug has since made a return as a second-line therapy, and is on track to being reimbursed in England.
The suits are an early test of the Arkansas law banning company ownership of PBMs and pharmacies in the state, as other states consider similar legislation.
An unintended consequence of a provision framed as an administrative change in the bill could significantly reduce medication adherence among low-income older adults and increase mortality, a study found.
Despite pushback by industry, the government is standing by its new statutory scheme rebate rates for branded medicines, including one that doubles the rate that companies must repay on the sales of newer products to the National Health Service to 31.3%.
Despite pushback by industry, the government is standing by its new statutory scheme rebate rates for branded medicines, including one that doubles the rate that companies must repay on the sales of newer products to the National Health Service to 31.3%.
EU authorities must “take advantage” of the upcoming Biotech Act to reassess the bloc’s policies and “offset existing challenges” for small and midsized enterprises, trade association EUCOPE has said.
The whole contract research organization industry is being impacted by the current volatility in the pharmaceutical industry.
